{"id":"al101","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4297269","moleculeType":"Small molecule","molecularWeight":"556.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K/AKT/mTOR pathway, AL101 exerts its anti-tumor effects. This pathway is crucial for cell proliferation and survival, and its inhibition can lead to apoptosis in cancer cells.","oneSentence":"AL101 is an inhibitor of the PI3K/AKT/mTOR pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:24.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors with PI3K/AKT/mTOR pathway alterations"}]},"trialDetails":[{"nctId":"NCT07105709","phase":"PHASE2","title":"Open-label Extension Study in Participants With Early Alzheimer's Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-14","conditions":"Alzheimer's Disease","enrollment":220},{"nctId":"NCT06079190","phase":"PHASE2","title":"Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-10-20","conditions":"Alzheimer's Disease","enrollment":367},{"nctId":"NCT04973683","phase":"PHASE1","title":"AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-30","conditions":"Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma","enrollment":14},{"nctId":"NCT04951310","phase":"NA","title":"COVID-19 Vaccinations With a Sweepstakes","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-06-07","conditions":"Covid19","enrollment":3827656},{"nctId":"NCT03777020","phase":"NA","title":"Service Dog Training Program for Military Veterans With PTSD","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-08-22","conditions":"Post Traumatic Stress Disorder","enrollment":60},{"nctId":"NCT04461600","phase":"PHASE2","title":"A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Ayala Pharmaceuticals, Inc,","startDate":"2020-08-14","conditions":"Triple Negative Breast Cancer","enrollment":18},{"nctId":"NCT03691207","phase":"PHASE2","title":"A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations","status":"COMPLETED","sponsor":"Ayala Pharmaceuticals, Inc,","startDate":"2018-12-14","conditions":"Adenoid Cystic Carcinoma","enrollment":87},{"nctId":"NCT04111666","phase":"PHASE1","title":"A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101","status":"COMPLETED","sponsor":"Alector Inc.","startDate":"2019-12-14","conditions":"Healthy","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS 906024","AL 101","AL-101","BM-0018","BM0018"],"phase":"phase_2","status":"active","brandName":"AL101","genericName":"AL101","companyName":"Ayala Pharmaceuticals, Inc,","companyId":"ayala-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL101 is an inhibitor of the PI3K/AKT/mTOR pathway. Used for Solid tumors with PI3K/AKT/mTOR pathway alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}